Pathogenic Mutations and Rare Variants of the APC Gene Identified

Total Page:16

File Type:pdf, Size:1020Kb

Pathogenic Mutations and Rare Variants of the APC Gene Identified European Journal of Human Genetics (2002) 10, 505 – 510 ª 2002 Nature Publishing Group All rights reserved 1018 – 4813/02 $25.00 www.nature.com/ejhg ARTICLE Pathogenic mutations and rare variants of the APC gene identified in 75 Belgian patients with familial adenomatous polyposis by fluorescent enzymatic mutation detection (EMD) Genevie`ve Michils1, Sabine Tejpar1,2, Jean-Pierre Fryns1, Eric Legius1, Eric Van Cutsem2, Jean-Jacques Cassiman1 and Gert Matthijs*,1 1Center for Human Genetics, University of Leuven, Leuven, Belgium; 2Department of Gastro-enterology, University of Leuven, Leuven, Belgium Familial adenomatous polyposis (FAP) is a dominant inherited colorectal cancer syndrome which is caused by germline mutations in the adenomatous polyposis coli (APC) gene. Enzymatic mutation detection (EMD) has potential advantages over the standard protein truncation test (PTT) that is currently used in screening the APC gene for mutations. First we wanted to validate the EMD technique in comparison to PTT. Secondly, we wanted to develop an efficient working protocol for EMD screening of APC. Seventy-five unrelated patients were screened for mutations. All mutations that had previously been detected by PTT were also identified by EMD; the sizes of the cleavage fragments were as expected according to the position of the mutations within the amplicons. A new screening strategy based on EMD allows the analysis of the APC gene in 31 overlapping PCR fragments. In total, EMD efficiently detected the 26 truncating mutations in this series. In addition, two rare variants were also detected: the first is the typical Ashkenazi missense mutation I1307K while the second variant, E1317Q, has been identifed in Belgian patients and controls, and should no longer be considered as a pathogenic mutation, but rather classified as a polymorphism. European Journal of Human Genetics (2002) 10, 505 – 510. doi:10.1038/sj.ejhg.5200825 Keywords: enzymatic mutation detection; EMD; variants; hypermutable; FAP; adenomatous polyposis coli (APC); protein truncation test Introduction Familial adenomatous polyposis (FAP) is an autosomal 99, appearing at a later age and being still associated with dominant disorder characterised by the development of at an increased risk of cancer.1 The profuse phenotype is asso- least 100 colorectal adenomas at a young age (before 20 ciated with the appearance of more than five thousand years), some of which will progress to colorectal cancer polyps, whereas patients with the classical sparse phenotype one or two decades later. In addition to the classical form eventually develop one to two thousand polyps. The adeno- of FAP, an attenuated form was described: attenuated FAP matous polyposis coli (APC) gene was discovered in 1991,2,3 (AFAP) or attenuated adenomatous polyposis coli (AAPC), and the germline mutation spectrum is generally spread in which the number of polyps ranges between 10 and over its entire coding region. Hot spot regions for somatic mutations in colorectal tumors (mutation cluster region (MCR) in exon 15),4 and in desmoids (middle part of exon *Correspondence: G Matthijs, Center for Human Genetics, UZ Gasthuis- 15)5 are well characterised. The positions of the germline berg, Herestraat 49, B-3000 Leuven, Belgium. Tel: +32 16 346070; Fax: +32 16 346060; E-mail: [email protected] mutations correlate with the severity of the disease. For Received 23 July 2001; revised 18 April 2002; accepted 23 April 2002 example, in classical FAP, mutations are located between Enzymatic mutation detection for APC screening GMichilset al 506 codons 213 – 1249, whereas in the profuse phenotype muta- to the samples and incubation for 30 min at 378C followed. tions are located between codons 1250 – 1464.6 Mutations All the incubation steps were performed in a standard ther- in exon 9 and at the 5’ and the 3’ end of APC are also mocycler. EMD products were loaded on a 6% Long Ranger responsible for AFAP.7–9 Known germline and somatic Urea gel (SanverTech) and detected with an ALF DNA mutations can be found at the internet site address: sequencer (Amersham Pharmacia Biotech). PTT analysis of http://perso.curie.fr/Thierry.Soussi/APC.html#Ancrage3. exon 15 has been performed as described.11 Due to the extended mutation spectrum of the APC gene, Exon 6 has been screened for all patients using Denatur- and the size of the gene itself, there is a need for an effi- ing Gradient Gel Electrophoresis (DGGE) according to cient and sensitive mutation detection method. Currently Olschwang et al.18 the protein truncation test (PTT) is the technique most widely used to screen for mutations in the APC gene.10,11 Results However, PTT only allows the detection of truncating muta- PTT was initially used for the APC exon 15 screening of a tions. While over 90% of pathogenic mutations detected in series of 40 patients. It has been performed in four overlap- classic FAP are truncating mutations, missense mutations, ping fragments. In fifteen out of the 40 patients, a polymorphisms and variants of unknown significance that truncated peptide was detected; sequencing revealed ten have been reported are spread over the whole gene. The different alterations that were all localized in the first half majority of these would not have been detected by PTT of exon 15. (e.g. E1317Q, S1971R, A2119V).12,13 For comparisons, these samples were submitted to EMD We wanted to evaluate the feasibility and efficiency of in amplicons of several sizes, ranging from 277 to 910 bp. enzymatic mutation detection (EMD) screening of the The size of the cleavage peaks could be calculated according APC gene. This is potentially an easy, rapid and accurate to the position of the mutation within the tested amplicon. method that has the advantage of detecting all types of As both primers were labelled, two peaks were expected for mutations.14 EMD is based on the properties of the T4 detection after cleavage. All peaks were positively detected endonuclease VII that has the ability to detect mismatches and some mutations were observed in overlapping ampli- in a double-stranded DNA molecule and to cleave the DNA cons (Table 1). strand at this locus.15 The cleavage products can easily be The samples showing a negative PTT result have been detected after electrophoresis. EMD has been originally further analysed by EMD of the exons 1 – 14. A second developed from the enzymatic mismatch cleavage method series of 35 patients, which had not been previously tested (EMC),16 and has been improved to allow extended screen- ing. In this study, we aimed to validate EMD by comparing it Table 1 Germline mutations of the APC gene identified in to PTT. In addition, we established an efficacious screening Belgian FAP patients protocol which allows rapid scanning of all exons of APC. Exon Detection Mutation Codon (fragment) method Patient Subjects and methods DNA from clinically affected FAP or AFAP patients R216X 216 6 DGGE 187832 submitted for molecular diagnostic analysis was used for R232X 232 6 DGGE 191930 R302X 302 8 EMD 186794 this study. Lymphocyte DNA from patients and controls 1087 ins A 357 9 EMD 202032 was prepared using standard salt precipitations. S457X 457 10 EMD 179129 For EMD analysis of exon 15, amplicons of different sizes 1494 del C 491 11 EMD 207230 R499X 499 11 EMD 151913; 178620 were generated using several combinations of described 2128 del G 704 15-ac EMD 110175 2 primers. In addition, a few new primers were designed: c3 Y935X 935 15-ac/c3d PTT – EMD 38378 (forward) 5’-CACAAGCAAAGTCTCTATGGTG, h2 (reverse) 2911 del AATA 966 15-c3d/de PTT – EMD 30913 5’-TTTCTGCCTCTTTCTCTTGG, i3 (forward) 5’-ACCAAGA- 3104 del TT 1028 15-c3d/de PTT – EMD 175491 3201 del ACAAA 1061 15-de EMD 153316 GAAAGAGGCAGAA. The amplicons were : a-c, c3-d, d-e, f- Q1175X 1175 15-ff EMD 228789 f, g-h, h-h2, i3-i, j-k, k-l, m-n, o-p, q-r, s-t, u-v, and v-w. S1194X 1194 15-ff PTT – EMD 180798 The remaining 16 segments of APC (1 – 9, 10, 11 – 14, and 3614 ins A 1199 15-ff PTT – EMD 35963 3945 del AAAGA 1309 15-gh PTT – EMD 167202; 167877; the alternative spliced exons 9A and 10A) were amplified 2,17 163927; 185236; as described. For each amplicon, both forward and 185266; 216937 reverse primers were labelled with fluorescein isothiocya- 4057 GC?A 1347 15-gh PTT – EMD 193859 nate (FITC). Fluorescently labelled PCR fragments were 4411 del AG 1465 15-gh/hh2 PTT – EMD 187805 4439 del C 1474 15-gh/hh2 PTT – EMD 177751 submitted to the EMD reaction with the Passport kit for 4630 del GA 1538 15-hh2 PTT – EMD 101206 ABI 377 detection (Amersham Pharmacia Biotech). Dena- Numbering of nucleotides (nt) and codons is related to the turation (958C, 4 min) was followed by a cooling step GenBank file M74088 (nt 1 in position 1 of cDNA; codon 1 is first from 958Cto378C at 0.028C/s. Enzyme was then added ATG at nucleotide 19 of cDNA). European Journal of Human Genetics Enzymatic mutation detection for APC screening G Michils et al 507 by PTT, was also submitted to EMD according to the presented protocol (see Subjects and methods). In total, 26 pathogenic APC mutations were identified in 75 FAP or AFAP patients (35%). They represent twenty different DNA alterations (nine deletions, two insertions, eight nonsense mutations and one GC?A mutation) (Table 1). The mutations were located in exons 6, 8, 9, 10, 11, and in fragments a to i of exon 15. Six patients carried the same 5 bp deletion at codon 1309. This particular mutation represents nearly a quarter of all positive samples in this study.
Recommended publications
  • Next-Generation Sequencing for Identifying a Novel/De Novo
    Martínez-Hernández et al. BMC Medical Genomics (2019) 12:68 https://doi.org/10.1186/s12920-019-0528-1 CASE REPORT Open Access Next-generation sequencing for identifying a novel/de novo pathogenic variant in a Mexican patient with cystic fibrosis: a case report Angélica Martínez-Hernández1, Julieta Larrosa2, Francisco Barajas-Olmos1, Humberto García-Ortíz1, Elvia C. Mendoza-Caamal3, Cecilia Contreras-Cubas1, Elaheh Mirzaeicheshmeh1, José Luis Lezana4 and Lorena Orozco1* Abstract Background: Mexico is among the countries showing the highest heterogeneity of CFTR variants. However, no de novo variants have previously been reported in Mexican patients with cystic fibrosis (CF). Case presentation: Here, we report the first case of a novel/de novo variant in a Mexican patient with CF. Our patient was an 8-year-old male who had exhibited the clinical onset of CF at one month of age, with steatorrhea, malabsorption, poor weight gain, anemia, and recurrent respiratory tract infections. Complete sequencing of the CFTR gene by next generation sequencing (NGS) revealed two different variants in trans, including the previously reported CF-causing variant c.3266G > A (p.Trp1089*, W1089*), that was inherited from the mother, and the novel/ de novo CFTR variant c.1762G > T (p.Glu588*). Conclusion: Our results demonstrate the efficiency of targeted NGS for making a rapid and precise diagnosis in patients with clinically suspected CF. This method can enable the provision of accurate genetic counselling, and improve our understanding of the molecular basis of genetic diseases. Keywords: Cystic fibrosis, Next generation sequencing, P.Trp1089*, P.Glu588*, Novel/de novo variant Background been detected, with the deletion of phenylalanine at pos- Cystic fibrosis (CF, MIM# 219700) is the most common ition 508 (c.1521_1523delCTT, p.Phe508del, F508del) autosomal recessive disorder among Caucasians.
    [Show full text]
  • Multi-Omics Analysis Defines Core Genomic Alterations in Pheochromocytomas and Paragangliomas
    ARTICLE Received 11 Aug 2014 | Accepted 5 Dec 2014 | Published 27 Jan 2015 DOI: 10.1038/ncomms7044 OPEN Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas Luis Jaime Castro-Vega1,2,*, Eric Letouze´3,*, Nelly Burnichon1,2,4,*, Alexandre Buffet1,2,4, Pierre-He´lie Disderot1,2, Emmanuel Khalifa1,2,4,Ce´line Loriot1,2, Nabila Elarouci3, Aure´lie Morin1,2,Me´lanie Menara1,2, Charlotte Lepoutre-Lussey1,2,5,Ce´cile Badoual1,2,6, Mathilde Sibony2,7, Bertrand Dousset2,8,9,10, Rossella Libe´2,9,10,11,12, Franck Zinzindohoue2,13, Pierre Franc¸ois Plouin1,2,5,12,Je´roˆme Bertherat2,9,10,11,12, Laurence Amar1,2,5, Aure´lien de Reynie`s3, Judith Favier1,2,y & Anne-Paule Gimenez-Roqueplo1,2,4,12,y Pheochromocytomas and paragangliomas (PCCs/PGLs) are neural crest-derived tumours with a very strong genetic component. Here we report the first integrated genomic examination of a large collection of PCC/PGL. SNP array analysis reveals distinct copy-number patterns associated with genetic background. Whole-exome sequencing shows a low mutation rate of 0.3 mutations per megabase, with few recurrent somatic mutations in genes not previously associated with PCC/PGL. DNA methylation arrays and miRNA sequencing identify DNA methylation changes and miRNA expression clusters strongly associated with messenger RNA expression profiling. Overexpression of the miRNA cluster 182/96/183 is specific in SDHB-mutated tumours and induces malignant traits, whereas silencing of the imprinted DLK1-MEG3 miRNA cluster appears as a potential driver in a subgroup of sporadic tumours.
    [Show full text]
  • High-Efficiency CRISPR/Cas9 Mutagenesis of the White Gene in the Milkweed Bug Oncopeltus Fasciatus
    | INVESTIGATION High-Efficiency CRISPR/Cas9 Mutagenesis of the white Gene in the Milkweed Bug Oncopeltus fasciatus Katie Reding and Leslie Pick1 Department of Entomology, University of Maryland, College Park, Maryland 20742 ORCID IDs: 0000-0003-2067-4232 (K.R.); 0000-0002-4505-5107 (L.P.) ABSTRACT In this manuscript, we report that clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 is highly efficient in the hemipteran Oncopeltus fasciatus. The white gene is well characterized in Drosophila where mutation causes loss of eye pigmentation; white is a reliable marker for transgenesis and other genetic manipulations. Accordingly, white has been targeted in a number of nonmodel insects to establish tools for genetic studies. Here, we generated mutations in the Of-white (Of-w) locus using CRISPR/Cas9. We found that Of-w is required for pigmentation throughout the body of Oncopeltus, not just the ommatidia. High rates of somatic mosaicism were observed in the injected generation, reflecting biallelic mutations, and a high rate of germline mutation was evidenced by the large proportion of heterozygous G1s. However, Of-w mutations are homozygous lethal; G2 homozygotes lacked pigment dispersion throughout the body and did not hatch, precluding the establishment of a stable mutant line. Embryonic and parental RNA interference (RNAi) were subsequently performed to rule out off-target mutations producing the observed phenotype and to evaluate the efficacy of RNAi in ablating gene function compared to a loss-of-function mutation. RNAi knockdowns phe- nocopied Of-w homozygotes, with an unusual accumulation of orange granules observed in unhatched embryos. This is, to our knowledge, the first CRISPR/Cas9-targeted mutation generated in Oncopeltus.
    [Show full text]
  • Cfdna Deconvolution Via NIPT of a Pregnant Woman After Bone Marrow
    Zhu et al. Human Genomics (2021) 15:14 https://doi.org/10.1186/s40246-021-00311-w PRIMARY RESEARCH Open Access cfDNA deconvolution via NIPT of a pregnant woman after bone marrow transplant and donor egg IVF Jianjiang Zhu1 , Feng Hui2, Xuequn Mao1, Shaoqin Zhang1, Hong Qi1* and Yang Du2* Abstract Cell-free DNA is known to be a mixture of DNA fragments originating from various tissue types and organs of the human body and can be utilized for several clinical applications and potentially more to be created. Non-invasive prenatal testing (NIPT), by high throughput sequencing of cell-free DNA (cfDNA), has been successfully applied in the clinical screening of fetal chromosomal aneuploidies, with more extended coverage under active research. In this study, via a quite unique and rare NIPT sample, who has undergone both bone marrow transplant and donor egg IVF, we investigated the sources of oddness observed in the NIPT result using a combination of molecular genetics and genomic methods and eventually had the case fully resolved. Along the process, we devised a clinically viable process to dissect the sample mixture. Eventually, we used the proposed scheme to evaluate the relatedness of individuals and the demultiplexed sample components following modified population genetics concepts, exemplifying a noninvasive prenatal paternity test prototype. For NIPT specific applicational concern, more thorough and detailed clinical information should therefore be collected prior to cfDNA-based screening procedure like NIPT and systematically reviewed when an abnormal report is obtained to improve genetic counseling and overall patient care. Keywords: NIPT, Target sequencing, Fetal fraction, IVF, Transplant, Prenatal diagnostic Introduction establishment of circulating tumor DNA (ctDNA) in the Cell-free DNA (cfDNA) is known to be a mixture from plasma of cancer patients [4].
    [Show full text]
  • Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis
    Medical Coverage Policy Effective Date ............................................. 7/15/2021 Next Review Date ......................................12/15/2021 Coverage Policy Number .................................. 0514 Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Table of Contents Related Coverage Resources Overview ........................................................ 2 Genetics Coverage Policy ............................................ 2 Genetic Testing Collateral File Genetic Counseling ...................................... 2 Recurrent Pregnancy Loss: Diagnosis and Treatment Germline Carrier Testing for Familial Infertility Services Disease .......................................................... 3 Preimplantation Genetic Testing of an Embryo........................................................... 4 Preimplantation Genetic Testing (PGT-A) .. 5 Sequencing–Based Non-Invasive Prenatal Testing (NIPT) ............................................... 5 Invasive Prenatal Testing of a Fetus .......... 6 Germline Mutation Reproductive Genetic Testing for Recurrent Pregnancy Loss ...... 6 Germline Mutation Reproductive Genetic Testing for Infertility ..................................... 7 General Background .................................... 8 Genetic Counseling ...................................... 8 Germline Genetic Testing ............................ 8 Carrier Testing for Familial Disease ........... 8 Preimplantation Genetic Testing of an Embryo..........................................................
    [Show full text]
  • The Genetic Complexity of Prostate Cancer
    G C A T T A C G G C A T genes Review The Genetic Complexity of Prostate Cancer Eva Compérat 1,2,3,*, Gabriel Wasinger 3 , André Oszwald 3 , Renate Kain 3 , Geraldine Cancel-Tassin 1 and Olivier Cussenot 1,4 1 CeRePP/GRC5 Predictive Onco-Urology, Sorbonne University, 75020 Paris, France; [email protected] (G.C.-T.); [email protected] (O.C.) 2 Department of Pathology, Hôpital Tenon, Sorbonne University, 75020 Paris, France 3 Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria; [email protected] (G.W.); [email protected] (A.O.); [email protected] (R.K.) 4 Department of Urology, Hôpital Tenon, Sorbonne University, 75020 Paris, France * Correspondence: [email protected]; Tel.: +33-658246024 Received: 28 September 2020; Accepted: 23 November 2020; Published: 25 November 2020 Abstract: Prostate cancer (PCa) is a major concern in public health, with many genetically distinct subsets. Genomic alterations in PCa are extraordinarily complex, and both germline and somatic mutations are of great importance in the development of this tumor. The aim of this review is to provide an overview of genetic changes that can occur in the development of PCa and their role in potential therapeutic approaches. Various pathways and mechanisms proposed to play major roles in PCa are described in detail to provide an overview of current knowledge. Keywords: prostate cancer; germline mutations; somatic mutations; PTEN; TMPRSS2; ERG; androgen receptors 1. Introduction Prostate cancer (PCa) is a major concern in public health, with more than 1.1 million cases worldwide detected every year [1].
    [Show full text]
  • A Germline Or De Novo Mutation in Two Families with Gaucher Disease: Implications for Recessive Disorders
    European Journal of Human Genetics (2013) 21, 115–117 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders Hamid Saranjam1, Sameer S Chopra2,3, Harvey Levy3, Barbara K Stubblefield1, Emerson Maniwang1, Ian J Cohen4,5, Hagit Baris4,5, Ellen Sidransky*,1 and Nahid Tayebi1 Gaucher disease (GD) is an autosomal recessive storage disorder that most commonly results from the inheritance of one identifiable mutant glucocerebrosidase (GBA1) allele from each parent. Here, we report two cases of type 2 GD resulting from the inheritance of one identifiable paternal mutant allele and one allele that likely resulted from a maternal germline mutation. Germline mutations or mosiacism are not generally associated with autosomal recessive disorders. The probands from the two unrelated families had the same maternal mutation, leu444pro, that we propose resulted from a de novo maternal germline mutation occurring at this known ‘hotspot’ for mutation. This first report of a germline mutation for a common point mutation leu444pro (c.1448 T4C;p.leu483pro) in GD has significant implications for molecular diagnostics and genetic counseling in recessive disorders. European Journal of Human Genetics (2013) 21, 115–117; doi:10.1038/ejhg.2012.105; published online 20 June 2012 Keywords: acute neuronopathic Gaucher disease; glucocerebrosidase; germline mutation; DNA mutational analysis; molecular diagnostic INTRODUCTION However, in both cases, the second mutant allele, leu444pro, was Gaucher disease (GD), the most common lysosomal storage disorder, not detected in the mother. This prompted us to explore whether the results from the autosomal recessively inherited deficiency of gluco- leu444pro mutation might have resulted from a maternal germline cerebrosidase (GCase, EC 3.2.1.45).1,2 GD is subdivided into three mutation in these families.
    [Show full text]
  • CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
    Published OnlineFirst August 16, 2016; DOI: 10.1158/0008-5472.CAN-16-1272 Cancer Tumor and Stem Cell Biology Research CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma Josephine Walton1,2, Julianna Blagih3, Darren Ennis1, Elaine Leung1, Suzanne Dowson1, Malcolm Farquharson1, Laura A. Tookman4, Clare Orange5, Dimitris Athineos3, Susan Mason3, David Stevenson3, Karen Blyth3, Douglas Strathdee3, Frances R. Balkwill2, Karen Vousden3, Michelle Lockley4, and Iain A. McNeish1,4 Abstract – – There is a need for transplantable murine models of ovarian ating novel ID8 derivatives that harbored single (Trp53 / )or – – – – high-grade serous carcinoma (HGSC) with regard to mutations in double (Trp53 / ;Brca2 / ) suppressor gene deletions. In these the human disease to assist investigations of the relationships mutants, loss of p53 alone was sufficient to increase the growth between tumor genotype, chemotherapy response, and immune rate of orthotopic tumors with significant effects observed on the microenvironment. In addressing this need, we performed whole- immune microenvironment. Specifically, p53 loss increased exome sequencing of ID8, the most widely used transplantable expression of the myeloid attractant CCL2 and promoted the model of ovarian cancer, covering 194,000 exomes at a mean infiltration of immunosuppressive myeloid cell populations into – – – – depth of 400Â with 90% exons sequenced >50Â. We found no primary tumors and their ascites. In Trp53 / ;Brca2 / mutant functional mutations in genes characteristic of HGSC (Trp53, cells, we documented a relative increase in sensitivity to the PARP Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally inhibitor rucaparib and slower orthotopic tumor growth – – active. Homologous recombination in ID8 remained intact in compared with Trp53 / cells, with an appearance of intratumoral þ functional assays.
    [Show full text]
  • Genomic and Transcriptomic Profiling of Carcinogenesis in Patients With
    Colon ORIGINAL RESEARCH Gut: first published as 10.1136/gutjnl-2019-319438 on 19 November 2019. Downloaded from Genomic and transcriptomic profiling of carcinogenesis in patients with familial adenomatous polyposis Jingyun Li,1,2,3,4 Rui Wang,1,2,4 Xin Zhou,1 Wendong Wang ,1 Shuai Gao,1 Yunuo Mao,1 Xinglong Wu,1 Limei Guo,5 Haijing Liu,5 Lu Wen,1 Wei Fu,1 Fuchou Tang 1,2,3,4 ► Additional material is ABSTRact published online only. To view, Objective Familial adenomatous polyposis (FAP) Significance of this study please visit the journal online is characterised by the development of hundreds to (http:// dx. doi. org/ 10. 1136/ What is already known on this subject? gutjnl- 2019- 319438). thousands of adenomas at different evolutionary stages in the colon and rectum that will inevitably progress to ► Familial adenomatous polyposis (FAP) is an For numbered affiliations see autosomal dominant syndrome primarily end of article. adenocarcinomas if left untreated. Here, we investigated the genetic alterations and transcriptomic transitions caused by inherited mutations in APC (adenomatous polyposis coli). Correspondence to from precancerous adenoma to carcinoma. Professor Fuchou Tang, Beijing Design Whole- exome sequencing, whole- genome ► Patients with FAP will develop hundreds Advanced Innovation Center sequencing and single- cell RNA sequencing were to thousands of adenomas in the colon for Genomics, Department of performed on matched adjacent normal tissues, and rectum that will inevitably progress to General Surgery, College of Life adenocarcinomas if left untreated. Sciences, Third Hospital, Peking multiregionally sampled adenomas at different Early prevention of FAP is challenging, and the University, Beijing 100871, stages and carcinomas from six patients with FAP ► China; and one patient with MUTYH- associated polyposis standard of care for classical FAP is prophylactic tangfuchou@ pku.
    [Show full text]
  • Misdiagnosis of Li-Fraumeni Syndrome in a Patient with Clonal Hematopoiesis and a Somatic TP53 Mutation
    461 Molecular Insights in Patient Care Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation Rachel L. Mitchell, MDa; Cory Kosche, BSa; Kelly Burgess, MS, CGCa; Shreya Wadhwa, BSa; Lela Buckingham, MDb; Ritu Ghai, MDb; Jacob Rotmensch, MDc; Oleksandra Klapko, BSa; and Lydia Usha, MDa Abstract Li-Fraumeni syndrome (LFS) is a rare genetic disorder that confers a high risk of developing certain malignancies at a young age. It is caused by germline mutations in the TP53 gene and is typically diagnosed by sequencing this gene in blood cells. The presence of a mutation in ap- proximately half of the DNA reads (allelic fraction of 50%) is an indicator of a germline mutation, such as that in LFS. Clonal hematopoiesis (CH) is an expansion of a hematopoietic clone containing a somatic driver mutation with a low allelic fraction, usually not more than 10% to 20%. This report presents a patient with fallopian tube carcinoma who underwent multigene panel testing for cancer predisposition and was found to have a mutation in the TP53 gene, c.733G>T (p.Gly245Cys). Since the TP53 mutation had an allelic fraction of approximately 50%, it was interpreted as being germline, and the patient was diagnosed as having LFS. A year later, she developed acute myelogenous leukemia. Subsequent mutational analysis showed that the TP53 mutation was absent in her benign tissue sample but present in leukemic cells. Furthermore, sequencing of the fallopian tube tumor tissue revealed a different TP53 gene mutation, c.818G>T (p.Arg273Leu). These observations confirmed that the previously identified mutation in her blood was somatic rather than germline and that she had CH at the time of genetic testing.
    [Show full text]
  • Intestinal Cancer in Patients with a Germline Mutation in the Down-Regulated in Adenoma (DRA) Gene
    Oncogene (1998) 16, 681 ± 684 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 SHORT REPORT Intestinal cancer in patients with a germline mutation in the down-regulated in adenoma (DRA) gene Akseli Hemminki1, Pia HoÈ glund1, Eero Pukkala2, Reijo Salovaara1,3, Heikki JaÈ rvinen4, Reijo Norio5 and Lauri A Aaltonen1 Departments of 1Medical Genetics, and 3Pathology, Haartman Institute, PO Box 21 (Haartmaninkatu 3), 00014 University of Helsinki, Finland; 2Finnish Cancer Registry, Liisankatu 21 B, 00171 Helsinki, Finland; 4Second Department of Surgery, Helsinki University Central Hospital, Haartmaninkatu 4, 00250 Helsinki, Finland; 5Department of Medical Genetics, the Family Federation of Finland, PO Box 849 (Kalevankatu 16), 00101 Helsinki, Finland A recent study has revealed that germline mutations of and in dedierentiated states of mucosa, such as in the down-regulated in adenoma (DRA) gene are a likely embryonic tissues or in neoplasia, DRA expression is cause of a recessive intestinal absorption defect, not detected (Schweinfest et al., 1993; Silberg et al., congenital chloride diarrhea. This ®nding was in 1995; HoÈ glund et al., 1996). Although the association accordance with previous works showing that DRA between lost DRA expression and neoplasia is encodes a sodium independent transporter for sulfate apparent, it is not known if this loss has a role in and oxalate. Although DRA was originally reported as a tumorigenesis, or if it is merely a consequence of the candidate tumor suppressor, these studies have ques- dedierentiated status of the epithelium. tioned the relevance of DRA in cancer. To evaluate Congenital chloride diarrhea (CLD) is an autosomal whether further studies on the role of DRA in recessive disorder characterized by voluminous watery tumorigenesis are still of interest, we examined whether stools containing a high concentration of chloride individuals carrying germline DRA mutations have an (McKusick, 1994).
    [Show full text]
  • The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington's Disease
    Journal of Huntington’s Disease 10 (2021) 7–33 7 DOI 10.3233/JHD-200429 IOS Press Review The Contribution of Somatic Expansion of the CAG Repeat to Symptomatic Development in Huntington’s Disease: A Historical Perspective Darren G. Monckton∗ Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK Abstract. The discovery in the early 1990s of the expansion of unstable simple sequence repeats as the causative mutation for a number of inherited human disorders, including Huntington’s disease (HD), opened up a new era of human genetics and provided explanations for some old problems. In particular, an inverse association between the number of repeats inherited and age at onset, and unprecedented levels of germline instability, biased toward further expansion, provided an explanation for the wide symptomatic variability and anticipation observed in HD and many of these disorders. The repeats were also revealed to be somatically unstable in a process that is expansion-biased, age-dependent and tissue-specific, features that are now increasingly recognised as contributory to the age-dependence, progressive nature and tissue specificity of the symptoms of HD, and at least some related disorders. With much of the data deriving from affected individuals, and model systems, somatic expansions have been revealed to arise in a cell division-independent manner in critical target tissues via a mechanism involving key components of the DNA mismatch repair pathway. These insights have opened new approaches to thinking about how the disease could be treated by suppressing somatic expansion and revealed novel protein targets for intervention.
    [Show full text]